• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

KCNJ5 突变与欧洲非糖皮质激素可治愈型家族性醛固酮增多症家系相关。

KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism.

机构信息

Division of Internal Medicine and Hypertension, University of Torino, Torino, Italy.

出版信息

Hypertension. 2012 Feb;59(2):235-40. doi: 10.1161/HYPERTENSIONAHA.111.183996. Epub 2011 Dec 27.

DOI:10.1161/HYPERTENSIONAHA.111.183996
PMID:22203740
Abstract

Primary aldosteronism is the most frequent cause of endocrine hypertension. Three forms of familial hyperaldosteronism (FH) have been described, named FH-I to -III. Recently, a mutation of KCNJ5 has been shown to be associated with FH-III, whereas the cause of FH-II is still unknown. In this study we searched for mutations in KCNJ5 in 46 patients from 21 families with FH, in which FH-I was excluded. We identified a new germline G151E mutation in 2 primary aldosteronism-affected subjects from an Italian family and 3 somatic mutations in aldosterone-producing adenomas, T158A described previously as a germline mutation associated with FH-III, and G151R and L168R both described as somatic mutations in aldosterone-producing adenoma. The phenotype of the family with the G151E mutation was remarkably milder compared with the previously described American family, in terms of both clinical and biochemical parameters. Furthermore, patients with somatic KCNJ5 mutations displayed a phenotype indistinguishable from that of sporadic primary aldosteronism. The functional characterization of the effects of the G151E mutation in vitro showed a profound alteration of the channel function, with loss of K(+) selectivity, Na(+) influx, and membrane depolarization. These alterations have been postulated to be responsible for voltage gate Ca(2+) channel activation, increase in cytosolic calcium, and stimulation of aldosterone production and adrenal cell proliferation. In conclusion, we describe herein a new mutation in the KCNJ5 potassium channel associated with FH-III, responsible for marked alterations of channel function but associated with a mild clinical and hormonal phenotype.

摘要

原醛症是内分泌性高血压最常见的病因。现已描述了三种家族性醛固酮增多症(FH)的形式,分别命名为 FH-I 至 FH-III。最近,已证明 KCNJ5 的突变与 FH-III 相关,而 FH-II 的病因仍不清楚。在这项研究中,我们在 21 个 FH 家族的 46 名患者中寻找 KCNJ5 的突变,其中排除了 FH-I。我们在一个意大利家族的 2 名原醛症受影响的受试者和 3 个醛固酮瘤中发现了一个新的胚系 G151E 突变,以前曾描述 T158A 为与 FH-III 相关的胚系突变,而 G151R 和 L168R 均为醛固酮瘤中的体细胞突变。与之前描述的美国家族相比,具有 G151E 突变的家族的表型在临床和生化参数方面都明显较轻。此外,具有体细胞 KCNJ5 突变的患者表现出与散发性原醛症无法区分的表型。体外 G151E 突变的功能特征表明,通道功能发生了深刻改变,丧失了 K(+)选择性、Na(+)内流和膜去极化。这些改变被认为是电压门控 Ca(2+)通道激活、细胞内钙增加以及刺激醛固酮产生和肾上腺细胞增殖的原因。总之,我们在此描述了一种与 FH-III 相关的 KCNJ5 钾通道的新突变,该突变导致通道功能发生明显改变,但与轻度临床和激素表型相关。

相似文献

1
KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism.KCNJ5 突变与欧洲非糖皮质激素可治愈型家族性醛固酮增多症家系相关。
Hypertension. 2012 Feb;59(2):235-40. doi: 10.1161/HYPERTENSIONAHA.111.183996. Epub 2011 Dec 27.
2
a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III.一个导致家族性醛固酮增多症 III 型的新型 Y152C KCNJ5 突变。
J Clin Endocrinol Metab. 2013 Nov;98(11):E1861-5. doi: 10.1210/jc.2013-2428. Epub 2013 Sep 13.
3
Primary Aldosteronism: KCNJ5 Mutations and Adrenocortical Cell Growth.原醛症:KCNJ5 突变与肾上腺皮质细胞生长。
Hypertension. 2019 Oct;74(4):809-816. doi: 10.1161/HYPERTENSIONAHA.119.13476. Epub 2019 Aug 26.
4
Role of KCNJ5 in familial and sporadic primary aldosteronism.KCNJ5 在家族性和散发性原发性醛固酮增多症中的作用。
Nat Rev Endocrinol. 2013 Feb;9(2):104-12. doi: 10.1038/nrendo.2012.230. Epub 2012 Dec 11.
5
The genetic basis of primary aldosteronism.原发性醛固酮增多症的遗传学基础。
Curr Hypertens Rep. 2012 Apr;14(2):120-4. doi: 10.1007/s11906-012-0255-x.
6
Familial hyperaldosteronism type III a novel case and review of literature.家族性醛固酮增多症 III 型:一例新病例及文献复习。
Rev Endocr Metab Disord. 2019 Mar;20(1):27-36. doi: 10.1007/s11154-018-9481-0.
7
Familial hyperaldosteronism type III.III型家族性醛固酮增多症
J Hum Hypertens. 2017 Dec;31(12):776-781. doi: 10.1038/jhh.2017.34. Epub 2017 Apr 27.
8
Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis.在 HAC-15 细胞中表达钾通道突变体 KCNJ5 T158A 会增加醛固酮的合成。
Endocrinology. 2012 Apr;153(4):1774-82. doi: 10.1210/en.2011-1733. Epub 2012 Feb 7.
9
Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature.伴有KCNJ5基因突变的III型家族性醛固酮增多症中基因型与表型的不一致相关性:一例患者报告及文献综述
Horm Res Paediatr. 2014;82(2):138-42. doi: 10.1159/000358197. Epub 2014 May 10.
10
Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism.在原发性醛固酮增多症的大样本散发病例中,种系突变和罕见编码单核苷酸多态性在 KCNJ5 钾通道中的作用。
Hypertension. 2014 Apr;63(4):783-9. doi: 10.1161/HYPERTENSIONAHA.113.02234. Epub 2014 Jan 13.

引用本文的文献

1
Ion channel traffic jams: the significance of trafficking deficiency in long QT syndrome.离子通道交通堵塞:长QT综合征中转运缺陷的意义。
Cell Discov. 2025 Jan 10;11(1):3. doi: 10.1038/s41421-024-00738-0.
2
Genetic Testing for Primary Aldosteronism in SPAIN: Results From the SPAIN-ALDO Registry and Review of the Literature.西班牙原发性醛固酮增多症的基因检测:来自西班牙醛固酮增多症(SPAIN-ALDO)注册研究的结果及文献综述
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1573-e1579. doi: 10.1210/clinem/dgae523.
3
Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism.
家族性与散发性原发性醛固酮增多症患者的临床和激素表现差异。
Front Endocrinol (Lausanne). 2024 Mar 1;15:1336306. doi: 10.3389/fendo.2024.1336306. eCollection 2024.
4
Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism.原发性醛固酮增多症的筛查与诊断。参与原发性醛固酮增多症管理的所有西班牙学会的共识文件。
Endocrine. 2024 Jul;85(1):99-121. doi: 10.1007/s12020-024-03751-1. Epub 2024 Mar 6.
5
Primary aldosteronism: molecular medicine meets public health.原发性醛固酮增多症:分子医学与公共卫生的交汇。
Nat Rev Nephrol. 2023 Dec;19(12):788-806. doi: 10.1038/s41581-023-00753-6. Epub 2023 Aug 23.
6
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.原发性醛固酮增多症相关性高血压的治疗:新方法与未来展望。
Endocr Rev. 2024 Jan 4;45(1):125-170. doi: 10.1210/endrev/bnad026.
7
Cardiovascular and metabolic characters of somatic mutations in primary aldosteronism.原发性醛固酮增多症中体细胞突变的心血管和代谢特征。
Front Endocrinol (Lausanne). 2023 Mar 6;14:1061704. doi: 10.3389/fendo.2023.1061704. eCollection 2023.
8
Hereditary Endocrine Tumor Registries.遗传性内分泌肿瘤登记处。
J Endocr Soc. 2022 Dec 23;7(3):bvac194. doi: 10.1210/jendso/bvac194. eCollection 2023 Jan 6.
9
A narrative review of Hyporeninemic hypertension-an indicator for monogenic forms of hypertension.低肾素性高血压——单基因形式高血压的一个指标的叙述性综述。
Pediatr Med. 2022 May;5. doi: 10.21037/pm-21-48. Epub 2022 May 28.
10
Disorders of the adrenal cortex: Genetic and molecular aspects.肾上腺皮质疾病:遗传与分子方面。
Front Endocrinol (Lausanne). 2022 Aug 29;13:931389. doi: 10.3389/fendo.2022.931389. eCollection 2022.